• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Th17细胞在复发缓解型多发性硬化症（RRMS）以及继发进展型多发性硬化症（SPMS）中均有所增加，而Th17的其他多种表型仅在RRMS中增加。

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only.

作者信息

Kalra S, Lowndes C, Durant L, Strange R C, Al-Araji A, Hawkins Clive P, Curnow S John

机构信息

Royal Stoke MS Centre of Excellence, Neurology Department, University Hospital North Midlands NHS Trust, UK.

Centre for Translational Inflammation Research, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, UK.

出版信息

Mult Scler J Exp Transl Clin. 2020 Jan 28;6(1):2055217319899695. doi: 10.1177/2055217319899695. eCollection 2020 Jan-Mar.

DOI:10.1177/2055217319899695
PMID:32064115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6990617/
Abstract

BACKGROUND

The nature and extent of inflammation seen in multiple sclerosis (MS) varies throughout the course of the disease. Changes seen in CD4+ T-helper cells in relapsing-remitting (RR) MS and secondary progressive (SP) MS might differ qualitatively and/or quantitatively.

OBJECTIVE

The objective of this paper is to study the frequencies of all major CD4+ T-helper subtypes - Th17, Th22 and Th1 lineage cells - in relapse, remission and secondary progression alongside CCR6 status, a chemokine receptor involved in migration of these cells into the central nervous system.

METHODS

We compared 100 patients (50 RRMS and 50 SPMS) and 50 healthy volunteers and performed flow cytometric analysis of lymphocytes in blood samples.

RESULTS

We demonstrated raised frequencies of various cell types along the Th17 axis; Th17, Th17.1 (IL-17+ interferon gamma+) and dual IL-17+ IL-22+ cells in RRMS. Th22 and CCR6+ Th1 cells (nonclassical Th1) were also increased in RRMS. All these cells were CCR6+. Only Th17 frequencies were elevated in SPMS.

CONCLUSIONS

Increased frequencies of Th17 cells are implicated both in RRMS and SPMS. The CCR6 pathway includes Th17, Th22 and Th1 nonclassical cells, of which Th22 and Th1 cells represent the greatest subsets in MS.

摘要

背景

多发性硬化症（MS）中炎症的性质和程度在疾病过程中各不相同。复发缓解型（RR）MS和继发进展型（SP）MS中CD4 +辅助性T细胞的变化可能在质量和/或数量上有所不同。

目的

本文的目的是研究复发期、缓解期和继发进展期所有主要CD4 +辅助性T细胞亚型（Th17、Th22和Th1谱系细胞）的频率以及CCR6状态，CCR6是一种参与这些细胞迁移到中枢神经系统的趋化因子受体。

方法

我们比较了100例患者（50例RRMS和50例SPMS）和50名健康志愿者，并对血样中的淋巴细胞进行了流式细胞术分析。

结果

我们证明了RRMS中沿Th17轴的各种细胞类型的频率升高；Th17、Th17.1（IL-17 +干扰素γ+）和双IL-17 + IL-22 +细胞。RRMS中Th22和CCR6 + Th1细胞（非经典Th1）也增加。所有这些细胞均为CCR6 +。SPMS中仅Th17频率升高。

结论

RRMS和SPMS中均涉及Th17细胞频率增加。CCR6途径包括Th17、Th22和非经典Th1细胞，其中Th22和Th1细胞是MS中最大的亚群。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/942e8c341cd4/10.1177_2055217319899695-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/901c2a4ca44e/10.1177_2055217319899695-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/3466aabea74d/10.1177_2055217319899695-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/942e8c341cd4/10.1177_2055217319899695-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/901c2a4ca44e/10.1177_2055217319899695-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/3466aabea74d/10.1177_2055217319899695-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/71b5/6990617/942e8c341cd4/10.1177_2055217319899695-fig3.jpg

相似文献

1
Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only.Th17细胞在复发缓解型多发性硬化症（RRMS）以及继发进展型多发性硬化症（SPMS）中均有所增加，而Th17的其他多种表型仅在RRMS中增加。
Mult Scler J Exp Transl Clin. 2020 Jan 28;6(1):2055217319899695. doi: 10.1177/2055217319899695. eCollection 2020 Jan-Mar.
2
Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.进行性多发性硬化症中的系统性炎症涉及滤泡辅助性 T 细胞、Th17 细胞和活化的 B 细胞，并与进展相关。
PLoS One. 2013;8(3):e57820. doi: 10.1371/journal.pone.0057820. Epub 2013 Mar 1.
3
Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes.Th1细胞和Th17细胞以及相关细胞因子可区分临床孤立综合征和多发性硬化症的不同表型。
Front Immunol. 2017 Jun 30;8:753. doi: 10.3389/fimmu.2017.00753. eCollection 2017.
4
Th22 cells are expanded in multiple sclerosis and are resistant to IFN-β.Th22 细胞在多发性硬化症中扩增，并对 IFN-β 有抗性。
J Leukoc Biol. 2014 Dec;96(6):1155-64. doi: 10.1189/jlb.5A0813-463RR. Epub 2014 Aug 5.
5
Existence of Th22 in children and evaluation of IL-22 + CD4 + T, Th17, and other T cell effector subsets from healthy children compared to adults.儿童体内Th22的存在以及与成人相比健康儿童中IL-22+CD4+T、Th17和其他T细胞效应亚群的评估。
BMC Immunol. 2016 Jun 23;17(1):20. doi: 10.1186/s12865-016-0158-8.
6
Distinct chemokine receptor and cytokine expression profile in secondary progressive MS.继发进展型多发性硬化症中独特的趋化因子受体和细胞因子表达谱
Neurology. 2001 Oct 23;57(8):1371-6. doi: 10.1212/wnl.57.8.1371.
7
T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.辅助性 T 细胞 17.1 与多发性硬化症的疾病活动相关：早期干预的新视角。
Brain. 2018 May 1;141(5):1334-1349. doi: 10.1093/brain/awy069.
8
Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.比较干扰素-β治疗的缓解-复发型多发性硬化症患者中反应性和非反应性 Th1 和 Th17 细胞中 miR-29b-3p 和 miR-326 的表达水平。
Iran J Allergy Asthma Immunol. 2020 Aug 25;19(4):416-425. doi: 10.18502/ijaai.v19i4.4116.
9
Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An Study.克拉屈滨治疗 RRMS 患者中选择 IFNγ+IL17+ T 细胞 - 一项队列研究。
Front Immunol. 2021 Dec 14;12:743010. doi: 10.3389/fimmu.2021.743010. eCollection 2021.
10
Chemokine receptor expression by inflammatory T cells in EAE.实验性自身免疫性脑脊髓炎中炎性T细胞的趋化因子受体表达
Front Cell Neurosci. 2014 Jul 4;8:187. doi: 10.3389/fncel.2014.00187. eCollection 2014.

引用本文的文献

1
Th17 cell pathogenicity in autoimmune disease.自身免疫性疾病中Th17细胞的致病性。
Exp Mol Med. 2025 Sep 1. doi: 10.1038/s12276-025-01535-9.
2
Aging-dependent change in Th17 and cytokine response in multiple sclerosis.多发性硬化症中Th17细胞及细胞因子反应随年龄的变化
J Neuroinflammation. 2025 Jun 5;22(1):150. doi: 10.1186/s12974-025-03474-8.
3
The Role of IL-17A in Mediating Inflammatory Responses and Progression of Neurodegenerative Diseases.白细胞介素-17A在介导神经退行性疾病炎症反应及进展中的作用

本文引用的文献

1
T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention.辅助性 T 细胞 17.1 与多发性硬化症的疾病活动相关：早期干预的新视角。
Brain. 2018 May 1;141(5):1334-1349. doi: 10.1093/brain/awy069.
2
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.多发性硬化症中的炎症性鞘内特征和皮质损伤。
Ann Neurol. 2018 Apr;83(4):739-755. doi: 10.1002/ana.25197.
3
CCR6 Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells.
Int J Mol Sci. 2025 Mar 11;26(6):2505. doi: 10.3390/ijms26062505.
4
Targeting cytokine networks in neuroinflammatory diseases.靶向神经炎症性疾病中的细胞因子网络。
Nat Rev Drug Discov. 2024 Nov;23(11):862-879. doi: 10.1038/s41573-024-01026-y. Epub 2024 Sep 11.
5
Berberine: A natural modulator of immune cells in multiple sclerosis.小檗碱：多发性硬化症中免疫细胞的天然调节剂。
Immun Inflamm Dis. 2024 Mar;12(3):e1213. doi: 10.1002/iid3.1213.
6
Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron.复发缓解型多发性硬化所致情绪症状和慢性疲劳综合征与免疫激活及红细胞异常有关。
Brain Sci. 2023 Jul 14;13(7):1073. doi: 10.3390/brainsci13071073.
7
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.奥法妥木单抗调节多发性硬化症患者炎症性 T 细胞反应和迁移潜能。
Neurol Neuroimmunol Neuroinflamm. 2022 Jun 7;9(4). doi: 10.1212/NXI.0000000000200004. Print 2022 Jul.
8
The Blood-Brain Barrier-A Key Player in Multiple Sclerosis Disease Mechanisms.血脑屏障——多发性硬化症发病机制中的关键因素。
Biomolecules. 2022 Apr 2;12(4):538. doi: 10.3390/biom12040538.
9
Treatment With Cladribine Selects IFNγ+IL17+ T Cells in RRMS Patients - An Study.克拉屈滨治疗 RRMS 患者中选择 IFNγ+IL17+ T 细胞 - 一项队列研究。
Front Immunol. 2021 Dec 14;12:743010. doi: 10.3389/fimmu.2021.743010. eCollection 2021.
10
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing-Remitting from Secondary Progressive Multiple Sclerosis. A Review.循环 miRNA 作为鉴别复发缓解型与继发进展型多发性硬化症的潜在生物标志物：综述。
Int J Mol Sci. 2021 Nov 2;22(21):11887. doi: 10.3390/ijms222111887.
多发性硬化症患者脑脊液中的CCR6辅助性T细胞以致病性非经典辅助性T1细胞和仅分泌粒细胞-巨噬细胞集落刺激因子的辅助性T细胞为主。
Brain Behav Immun. 2017 Aug;64:71-79. doi: 10.1016/j.bbi.2017.03.008. Epub 2017 Mar 20.
4
IL-22, GM-CSF and IL-17 in peripheral CD4+ T cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy.多发性硬化复发和缓解期间外周血CD4+ T细胞亚群中的白细胞介素-22、粒细胞-巨噬细胞集落刺激因子和白细胞介素-17。皮质类固醇疗法的影响。
PLoS One. 2017 Mar 16;12(3):e0173780. doi: 10.1371/journal.pone.0173780. eCollection 2017.
5
Distinct T cell signatures define subsets of patients with multiple sclerosis.不同的 T 细胞特征定义了多发性硬化症患者的亚群。
Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e278. doi: 10.1212/NXI.0000000000000278. eCollection 2016 Oct.
6
Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.多发性硬化症中的病变分布模式不同与不同的循环辅助性 T 细胞和辅助样先天淋巴细胞亚群有关。
Mult Scler. 2017 Jun;23(7):1025-1030. doi: 10.1177/1352458516662726. Epub 2016 Aug 1.
7
Defining secondary progressive multiple sclerosis.定义继发进展型多发性硬化症。
Brain. 2016 Sep;139(Pt 9):2395-405. doi: 10.1093/brain/aww173. Epub 2016 Jul 7.
8
A practical review of the neuropathology and neuroimaging of multiple sclerosis.多发性硬化症神经病理学与神经影像学的实用综述
Pract Neurol. 2016 Aug;16(4):279-87. doi: 10.1136/practneurol-2016-001381. Epub 2016 Mar 23.
9
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?辅助性T细胞17：那他珠单抗停药后多发性硬化症复发的预后标志物？
Mult Scler. 2017 Jan;23(1):114-118. doi: 10.1177/1352458516640609. Epub 2016 Jul 11.
10
Th Cell Diversity in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.实验性自身免疫性脑脊髓炎和多发性硬化症中的辅助性T细胞多样性
J Immunol. 2015 Sep 15;195(6):2552-9. doi: 10.4049/jimmunol.1501097. Epub 2015 Aug 3.